Peter Marks has been in the news recently for his role in overseeing the regulatory approval process for COVID-19 vaccines and treatments in the United States. As the Director of the Center for Biologics Evaluation and Research at the FDA, Marks has played a crucial role in evaluating the safety and efficacy of these medical products during the ongoing pandemic.
Prior to his current position, Peter Marks served as the Deputy Director of the Center for Biologics Evaluation and Research at the FDA. He is a prominent American hematologist oncologist with expertise in biologics and drug development. Marks has a strong background in regulatory science and has been instrumental in advancing innovative therapies for various diseases. His leadership and expertise have been particularly valuable in the FDA's response to the COVID-19 crisis, ensuring that safe and effective treatments are available to the public in a timely manner.